Global Cervical Cancer Diagnostics Market Report 2020-2030: COVID-19 Growth and Changes Expected - ResearchAndMarkets.com - Business Wire
Global Cervical Cancer Diagnostics Market Report 2020-2030: COVID-19 Growth and Changes Expected - ResearchAndMarkets.com - Business Wire |
- Global Cervical Cancer Diagnostics Market Report 2020-2030: COVID-19 Growth and Changes Expected - ResearchAndMarkets.com - Business Wire
- Jan. 1 - Global call goes out for HPV vaccination - FW Business
- A free 24-hour COVID test is available after a private Billings lab developed one from scratch - KTVQ Billings News
- Tony Hawk shares funny encounter at Covid testing site: ‘Are you related to Tony Hawk?’ - The Independent
| Posted: 30 Dec 2020 03:16 AM PST DUBLIN--(BUSINESS WIRE)--The "Cervical Cancer Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Cervical Cancer Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cervical cancer diagnostics market. Major players in the cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Co., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens Healthineers AG, Zilico, and Guided Therapeutics. The global cervical cancer diagnostics market is expected to decline from $8.02 billion in 2019 to $7.23 billion in 2020 at a compound annual growth rate (CAGR) of -9.87%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, especially postponement of non-emergency procedures. The market is then expected to recover and reach $8.62 billion in 2023 at a CAGR of 6.04%. The cervical cancer diagnostics market consists of sales of cervical cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce cervical cancer diagnostics devices. Cervical cancer is a type of cancer that occurs in cells of the cervix. These devices are used for the diagnosis of cervical cancer. North America was the largest region in the cervical cancer diagnostics market in 2019. In November 2018, QIAGEN, a German-based leading supplier of specimen and assay systems for diagnostic techniques, applied testing, academic and pharmaceutical research, collaborated with Self-screen BV and released the QIAscreen HPV PCR Test, a CE-IVD molecular diagnostic test for the detection of 15 recognized high-risk human papillomavirus (HPV) genotypes, which is considered to be the cause of cervical cancer. Self-screen BV is a VU University Medical Centre's spinoff company based in the Netherlands. The rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to drive the market for cervical cancer diagnostics. Increasing awareness among women about cervical cancer along with the emphasis by worldwide cancer organizations and governments on early testing for detecting cervical cancer and preventing it contributes to the growth of the market. The increased adoption of HPV home testing kits is expected to be the new trend in the market. The home-based HPV testing kits help women in collecting samples and getting the results conveniently on their own without going to the lab for screening. Therefore, companies are focusing on providing convenience to patients. The increased use of HPV vaccination is anticipated to hinder the cervical cancer diagnostics market. According to the World Health Organization, the 2 HPV types (16 and 18) cause 70% of cervical cancers and pre-cancerous cervical lesions, thereby giving human papillomavirus (HPV) vaccine is effectively reducing the numbers of cervical pre-cancerous lesions that may develop into cervical cancers. The study published in Cancer Epidemiology, Biomarkers & Prevention, in February 2019 supported the information from the Centers for Disease Control and Prevention (CDC) that states that among women who had been vaccinated, the share of precancers caused by HPV 16 and 18 dropped from 55.2% to 33.3% whereas, in unvaccinated women, the proportion dropped from 51% to 47.3%. The HPV vaccine is recommended by the Centers for Disease Control and Prevention (CDC) for all the kids and adults between the ages of 9 to 26. Therefore, the increased use of HPV vaccination is predicted to hinder the cervical cancer diagnostics market. Key Topics Covered: 1. Executive Summary 2. Cervical Cancer Diagnostics Market Characteristics 3. Cervical Cancer Diagnostics Market Size And Growth 3.1. Global Cervical Cancer Diagnostics Historic Market, 2015 - 2019, $ Billion 3.1.1. Drivers Of The Market 3.1.2. Restraints On The Market 3.2. Global Cervical Cancer Diagnostics Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion 3.2.1. Drivers Of The Market 3.2.2. Restraints On the Market 4. Cervical Cancer Diagnostics Market Segmentation 4.1. Global Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
4.2. Global Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Cervical Cancer Diagnostics Market Regional And Country Analysis 5.1. Global Cervical Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion 5.2. Global Cervical Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/rj44pp  |
| Jan. 1 - Global call goes out for HPV vaccination - FW Business Posted: 31 Dec 2020 09:00 PM PST  The connection between the human papillomavirus (HPV) and cervical cancer is well-documented by many health care organizations worldwide. Breaking the connection starts by understanding how HPV spreads and the importance of adolescents being vaccinated. "HPV is a very common virus in the population that is spread by sexual activity," Dr. Matthew Sutter, MD, MBA, FACEP, and Allen County's health commissioner, said. "About 80% of the U.S. population has had an HPV infection. Most people are asymptomatic, but there are several strains of the virus that can lead to various cancers including: cervical, vaginal, vulvar, penile, anal, throat and neck cancers. The HPV vaccination prevents infection from the HPV viruses that cause over 90% of these cancers." Recently, the World Health Organization (WHO) released a statement announcing a global strategy to end cervical cancer. Vaccination, screening and treatment are the three keys WHO identified as the way to eradicate cervical cancer. "The HPV vaccine is recommended for both girls and boys. Anyone who will become sexually active is at risk for this infection because it is so common. It is a prophylactic vaccine. So, the goal is to get it before any exposure happens," Dr. Sarah Turner, MD said. Adding, "Because of this, we recommend starting the series at 11 to12 years of age for both girls and boys though they can get it at any time after the age of 9. This may seem really young to be thinking about sexually transmitted infections but better to protect before any exposure than to find out afterwards and have to manage the infection." January has been designated as Cervical Health Awareness Month by the United States Congress. "Infection with HPV virus can change the cells of the female cervix in a way that predisposes it to cancer," Sutter said. "The HPV vaccine is very effective at preventing these infections." Adding, "These cancers take a long time to develop, but they can be completely avoided by not getting the virus in the first place." WHO estimates successfully implementing all three components could reduce more than 40% of new cervical cancer cases and 5 million related deaths by 2050. In the statement, WHO laid out plans to end cervical cancer by 2030. These include: • 90% of girls fully vaccinated with the HPV vaccine by 15 years of age • 70% of women screened using a high-performance test by age 35 and again by age 45 • 90% of women identified with cervical disease being treated Treatment includes 90% of women with pre-cancer treated and 90% of women with invasive cancer that is being managed. "The Human Papillomavirus (HPV) is associated with genital warts as well as several different cancers in both men and women," Turner, said. Adding, "There are many different types of HPV genotypes and they are classified as low or high risk. The low-risk genotypes are associated with genital warts and high-risk genotypes are associated with cancers." Currently, the HPV vaccine is effective in protecting against several genotypes of the virus. "The HPV vaccine helps reduce the risk of transmission of HPV by stimulating antibody production that will give protection to two of the low-risk genotypes and seven of the high-risk genotypes that are felt to cause more than 90% of cervical cancers. In doing this, it decreases the risk of developing genital warts or any of these cancers," Turner said. According to WHO, cervical is the fourth most common cancer among women globally. Without additional action, WHO estimates that by 2030 the annual number of new cases of cervical cancer could increase to 700,000. Some parents may be concerned about their children being vaccinated for a virus that is spread through sexual activity. They may worry that it could encourage sexual activity earlier, though some studies on this have found no correlation. Often additional information on the cancer-preventing vaccine can help parents make the decision to vaccinate, Sutter said. The WHO announcement represents a historic milestone. The agreement marks the first time 194 countries around the world have committed to eliminating cancer after adoption of the resolution at a recent meeting of the World Health Assembly. Besides getting vaccinated to guard against HPV at an early age, regular pap smears should still be part of a healthy woman's regimen. "Although the high-risk HPV plays a role in causing most cervical cancers, there are cervical cancers not associated with HPV," Turner said. "So, getting regular pap smears helps look at the cervical cells to monitor for any potential changes that may be precancerous. If we find any precancerous cells, we are usually able to monitor and treat them well before they turn into cancer." "...No one enjoys them, and no one finds them comfortable, but it is minimal discomfort compared to what you would go through in managing a cervical cancer."  |
| Posted: 30 Dec 2020 07:58 AM PST  BILLINGS — Getting a COVID-19 test result can take up to seven days in Yellowstone County, but a private Billings practice has that length of time beat – and they want the public to know about it. At Yellowstone Pathology Institute they've found a way to offer the public a COVID-19 test that's ready in just 24 hours, reversing the frustration felt by many when it comes to waiting for results. And the test is free with the help of CARES Act dollars. In Yellowstone County, positive case numbers have dipped slightly but the threat of a new mutated strain has been seen across the globe. "You know I don't think that we're quite done with this epidemic yet," said Dr. Angela Durden. She along with her colleagues have been monitoring the virus closely since its arrival. Yellowstone Pathology Institute is comprised of 8 total pathologists performing diagnoses based on technical results. The lab performs clinical pathology services including those associated with surgical pathology, cancer diagnostics and testing related to women's health such as pap smears and HPV screening, among other things. The lab employs 30 people. "We are experienced in laboratory testing that is our schtick, if you will," said Durden. "We said, why not? Why couldn't we try to do this right here locally." Durden is talking about testing for COVID-19. That's because months ago, supply shortages impacted medical laboratories everywhere. Shortages were seen in sample collection materials, testing kits and even staffing. Durden says the impact meant a "prolonged turnaround time" for COVID-19 results which ultimately extended quarantine times for people needing to get back to work, school and even those needing medical procedures. "And that's had a big impact on a lot of people," said Dr. Michael Brown. "People that need to travel people that want to go see their families." And the turnaround time is still a headache for many, most waiting as much as seven days in Yellowstone County to get their test results back from the county health department's community testing site. Meanwhile though at Yellowstone Pathology as many as 400 COVID-19 samples are coming in for testing and, in turn, going back out within just 24 hours. Brown says the lab could even handle a capacity of more. But how is it possible for this private practice to test for COVID? As Brown explains they had to build their own test kit from scratch and its not only effective it is considered the "gold standard" when it comes to testing. "Our test is a PCR based test so we're looking for the RNA In the virus," said Brown. Those with Yellowstone Pathologists say their practice of board-certified pathologists specialize in laboratory testing and the diagnosis of disease from tissue samples. "Our skill set and the independent nature of our practice have uniquely positioned us to act quickly in response to the testing shortage," said Durden. The materials for the test were sourced from manufacturers across the globe. "It has the highest performance characteristics that you see for tests on the market," said Brown. The practice also invested in additional robotic technology to create their own high-throughput test. "We rigorously validated our test to ensure its quality and performance and have submitted a request to the FDA for Emergency Use Authorization," said Durden. And they do it because there's a need. Waiting for a test result can be crippling, according to Durden. "You know it's easy to send your test off and then, you know, suddenly you're waiting a week because once your sample arrives in some lab in North Carolina they pretty much tell you get in line," she said. The mission is to provide some relief to state and local jurisdictions and eliminate that bottleneck, which leads to residents staying healthy in this global pandemic and moreover getting back to work in a struggling economy. "I think this test was born partially out of frustration because, you know, the lack of testing impacted us as well," said Durden. "I mean we also have a workforce in our laboratory and we also have people that we have to look out for." At first the samples were coming from referrals from area doctor's offices and other practices, but those with Yellowstone Pathology want the public to know anyone can get tested through their lab. Durden and Brown also say their test is not to be confused with several antigen based rapid COVID tests available online. Those tests can yield false negative and false positive results, said Durden. And coming at the end of January, Yellowstone Pathology plans to open a COVID-19 test collection center in the Yellowstone Medical Center where anyone can drop in, have their sample collected and get their results in hours.  |
| Posted: 31 Dec 2020 01:28 PM PST  Tony Hawk has shared another encounter with a person who almost recognised him – but ultimately failed to identify him as the skateboarding legend he is. The athlete frequently recounts stories of that kind on social media. On Friday, he shared the most recent occurrence, which he says happened at Covid testing site. Hawk said he was wearing a mask when he handed over paperwork to a test site worker. According to him, the test site worker went on to read out his name was well as those of two of his children, who were with him. "Okay... Anthony, Keegan and Kadence... Hawk? Are you guys related to Tony Hawk?" the test site worker asked. Hawk said he replied "yes", after which the woman asked in disbelief: "Are you pulling my leg?" To that, Hawk said he told the woman: "No, we are all directly related to him." Actor Patricia Arquette and musician Kimya Dawson emphasised with Hawk's plight. "People tell me I look like Patricia Arquette but they then tell me that she is taller than me," Arquette wrote in response to his tweet. "People tell me I have the same name as a singer they really like," Dawson shared. Hawk has shared similar accounts in the past. Comparable incidents have occurred at airports, on planes, and recently at a drive-thru line while the athlete was waiting for his food.  |
| You are subscribed to email updates from "hpv test" - Google News. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
Comments
Post a Comment